Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Fig. 2

Probabilistic sensitivity analysis cost-effectiveness scatterplots for the two subgroups based on DUAL I China (a) compared with liraglutide, (b) compared with degludec. The red line represents a WTP of CNY 257,094 per QALY gained. QALY, quality-adjusted life-year; CNY, Chinese yuan; WTP, willingness to pay

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us